NasdaqGS:LEGNBiotechs
Legend Biotech (LEGN) Is Up 13.9% After CARVYKTI Record Sales And REMS Removal News – Has The Bull Case Changed?
Legend Biotech recently reported record quarterly sales and profitability milestones for its CARVYKTI multiple myeloma therapy, alongside expanded global access and the past removal of FDA REMS restrictions that had limited how patients were monitored and allowed to drive.
These updates highlight how CARVYKTI has become one of the most widely used CAR-T treatments, supported by long-term survival data, growing manufacturing capacity and broader international launches that together could...